ClinicalTrials.gg
RecruitingNCT07512232TOWER-2Updated Apr 6, 2026

Intraoperative Rectal Lavage to Prevent Local Recurrence After Laparoscopic Mid-to-Low Rectal Cancer Resection: A Multicenter Randomized Trial

An interventional study of Rectal irrigation in Middle and Low Rectal Cancer and Rectal Cancer Surgery, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jun 2025, registered Mar 2026).
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,598
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 39 studies in Rectal Neoplasms by Sun Yat-sen University — 19 open to participants now, 24 under way, 6 of them phase 3. Rectal Neoplasms · Sun Yat-sen University.

Planned enrollment
Largest of 31
1,598 · median 100
Started
2025
with 9 others
No phase
8 of 39
5 open now
Primary completion
2028-05
later than 14 of 23 live
Registered
35th of 39
by date

Among the 39 studies in Rectal Neoplasms by Sun Yat-sen University, this one has the largest planned enrollment of the 31 interventional ones that give a count, is one of 10 that started in 2025, is one of 8 with no phase, reaches primary completion later than 14 of the 23 other live ones, and was the 35th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

19 of the 39 studies in Rectal Neoplasms by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Rectal Neoplasms by Sun Yat-sen University, or all of them as a file.
02

Study summary

Brief Summaries Trial Purpose The primary objective of this prospective, randomized, multicenter, open-label, parallel-controlled clinical trial is to evaluate whether intraoperative rectal irrigation during laparoscopic radical resection of low-to-mid rectal cancer reduces postoperative local recurrence rates compared to no irrigation. Secondary objectives include assessing overall survival, incidence of postoperative complications (e.g., anastomotic leakage, stenosis), and quality of life at 6 months (EORTC QLQ-C30 scale).

Participants Will:

  • Undergo laparoscopic radical resection with or without rectal irrigation (based on randomization);
  • Follow standardized Enhanced Recovery After Surgery (ERAS) protocols postoperatively;
  • Attend scheduled follow-ups at 3, 6, 12, 24, 36, and 60 months post-surgery, including clinical evaluations, imaging (CT/MRI), laboratory tests (CEA), and questionnaire assessments;
  • Maintain a symptom diary and record rescue inhaler usage (if applicable).
Read the detailed description

This prospective, multicenter, randomized, open-label, parallel-controlled clinical trial aims to evaluate the efficacy of intraoperative rectal lavage in preventing local recurrence after laparoscopic radical resection for mid-to-low rectal cancer. Despite significant improvements in rectal cancer outcomes through standardized total mesorectal excision (TME) techniques and neoadjuvant therapy, local recurrence remains a serious clinical challenge with poor prognosis. Evidence suggests that exfoliated tumor cells within the bowel lumen may contribute to anastomotic seeding and subsequent local recurrence. Intraoperative manipulation of the tumor and use of circular staplers during anastomosis may further increase the risk of tumor cell dissemination. Rectal lavage represents a potential strategy to eliminate these free intraluminal malignant cells through mechanical flushing and/or cytotoxic effects of lavage solutions.

The study will enroll approximately 1,598 patients (accounting for a 10% dropout rate) across multiple centers in China. Participants must be 18-75 years of age with histologically confirmed adenocarcinoma of the rectum, where the tumor's distal margin is located within 10 cm of the anal verge. All patients must be scheduled to undergo laparoscopic radical resection with sphincter preservation. Key exclusion criteria include history of other malignancies, abdominoperineal resection (Miles procedure) or Hartmann's procedure, emergency surgery for bowel obstruction, severe organ dysfunction contraindicating surgery, pregnancy or lactation, and serious psychiatric disorders.

Eligible participants will be randomly assigned to either the experimental group (rectal lavage with normal saline/povidone-iodine solution) or the control group (no rectal lavage). Both groups will receive standardized laparoscopic TME procedures performed by experienced surgical teams, followed by identical Enhanced Recovery After Surgery (ERAS) protocols. The primary endpoint is the rate of local recurrence. Secondary endpoints include overall survival, incidence of postoperative complications (anastomotic leakage, pelvic infection, wound infection, intra-abdominal hemorrhage, urinary tract infection) graded according to the Clavien-Dindo classification system, and quality of life at 6 months postoperatively assessed using the EORTC QLQ-C30 questionnaire.

Participants will undergo scheduled follow-up assessments at 3, 6, 12, 24, 36, and 60 months after surgery, including clinical evaluations, imaging studies (CT/MRI), laboratory tests (CEA levels), and quality of life questionnaires. The study hypothesizes that the local recurrence rate will be 6% in the rectal lavage group compared to 10% in the control group. With a two-sided alpha of 0.05 and 80% statistical power, this sample size will provide adequate power to detect this clinically significant difference. This investigation will provide high-quality evidence regarding the role of intraoperative rectal lavage in preventing local recurrence after laparoscopic resection of mid-to-low rectal cancer, potentially establishing a simple yet effective intervention to improve oncological outcomes in this patient population.

03

Conditions studied

  • Middle and Low Rectal Cancer
  • Rectal Cancer Surgery

Browse trials for

Keywords

  • rectal cancer
  • rectal Lavage
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 75 years old.
  • confirmed rectal adenocarcinoma.
  • Mid-to-low rectal cancer with the tumor lower margin located ≤10 cm from the anal verge.
  • Underwent laparoscopic radical resection for rectal cancer with sphincter preservation.
  • Without concomitant multiple primary .
  • Adequate organ function.
  • Patients or their family members were able to understand the study protocol, willing to participate in this study, and provided written .

Exclusion criteria

Exclusion Criteria:

  • Concomitant other or a history of prior malignancies.
  • Abdominal perineal resection (Miles' operation) or Hartmann's procedure.
  • Failure to open the peritoneal reflection during surgery.
  • History of previous pelvic floor surgery.
  • Emergency surgery due to bowel obstruction.
  • Severe hepatic, renal, cardiopulmonary, or coagulation dysfunction, or other severe comorbidities that render the patient unable to tolerate the procedure.
  • History of severe psychiatric disorders.
  • Pregnant or lactating women.
  • Any other clinical or laboratory conditions considered unsuitable for participation in the trial by the investigators.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,598 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Laparoscopic radical resection for rectal cancer followed by irrigation of the rectal cavity with normal saline / povidone-iodine

    Procedure: Rectal irrigation

  • No intervention
    control group

    No irrigation of the rectal stump was performed after laparoscopic radical resection for rectal cancer.

Interventions

  • ProcedureRectal irrigation

    Laparoscopic radical resection for rectal cancer followed by irrigation of the rectal cavity with normal saline / povidone-iodine

06

What researchers measure

Primary outcomes

  1. Postoperative local recurrence rate

    The postoperative local recurrence rate following laparoscopic radical resection for mid-to-low rectal cancer is defined as the number of patients with recurrence divided by the total number of subjects.

    Time frame: Within 3 years after radical resection of rectal cancer

Secondary outcomes

  1. Postoperative overall survival

    Postoperative Overall Survival (OS) is defined as the length of time from the date of surgery to the date of death from any cause.

    Time frame: Within 3 years after radical resection of rectal cancer

  2. Postoperative complications

    Postoperative complications-including anastomotic leakage, pelvic infection, surgical site infection, intra-abdominal hemorrhage, urinary tract infection, etc.-were graded according to the Clavien-Dindo classification system.

    Time frame: Within 3 years after radical resection of rectal cancer

  3. Health-related quality of life at 6 months

    Health-related quality of life at 6 months postoperatively was assessed using the EORTC QLQ-C30 questionnaire.

    Time frame: Within 3 years after radical resection of rectal cancer

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2028, 35 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 35 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 6, 2026
StartActual
Jun 1, 2025
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07512232
Responsible party
Yanhong Deng (chief physician, Sun Yat-sen University) — Principal investigator
First posted
Apr 6, 2026
Start date
Jun 1, 2025
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Apr 6, 2026

Study contacts

Liang Huang, Doctor
Contact
huangl75@sysu.edu.cn
+86 15989101216

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion